Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 21.95% | 24.71% | 19.09% | -33.30% | 22.07% |
Total Depreciation and Amortization | 7.59% | -0.96% | -10.68% | -15.16% | -9.70% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -39.71% | -18.73% | -40.72% | -45.08% | 25.52% |
Change in Net Operating Assets | 20.08% | -0.34% | 1.44% | 71.70% | -12.43% |
Cash from Operations | 17.77% | 18.32% | 10.97% | 22.80% | 20.63% |
Capital Expenditure | -29.41% | 72.28% | -1,194.59% | -276.83% | 96.38% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 288.53% | 8.21% | -39.16% | -258.43% | -145.35% |
Cash from Investing | 288.23% | 8.51% | -40.37% | -259.57% | -145.93% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -99.75% | -88.09% | -97.85% | 3.89% | 100,289.32% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -99.75% | -88.09% | -97.85% | -24.22% | 100,100.00% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -78.07% | 614.50% | -122.17% | -744.84% | 745.28% |